Reunion Neuroscience

top of page

Barclays Miami: Reunion Neuroscience received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)

CEO Greg Mayes describes the science behind luvesilocin, which is a prodrug of 4-OH-DiPT, a psilocybin-like compound, and discusses the company's plans for a phase 3 study. Plus, comments on two other indications the company is pursuing.

Company News

4 hours ago

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page

Barclays Miami: Reunion Neuroscience received Breakthrough Therapy Designation from FDA for its psychedelic based treatment for postpartum depression (PPD)

Follow BiotechTV

Sponsors

Sponsor Spotlight